Adagene (ADAG) announced the appointment of Dr. John Maraganore as Executive Advisor. Maraganore was CEO of Alnylam from 2002 to 2021, where he led the Company through global approvals and commercialization of four RNA interference therapeutic medicines.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene’s Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating
- Adagene Inc. Reports 2024 Financial Results and Progress
- Adagene Reports 2024 Financial Results and Advances Clinical Programs
- Adagene reports FY24 adjusted EPS (51c), consensus (58c)
- Adagene sees cash runway into late 2026